Author:
Dave Kaushalkumar,Luner Paul E.,Forness Cecile,Baker Doris,Jankovsky Corinne,Chen Shirlynn
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science,Agronomy and Crop Science,Ecology,Aquatic Science,General Medicine,Ecology, Evolution, Behavior and Systematics
Reference23 articles.
1. Neervannan S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug Metab Toxicol. 2006;2(5):715–31.
2. United States Code of Federal Regulations, Title 21, § 58.113.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=58.113
. Accessed 24 Nov. 2016.
3. Smith A, Whitsel M. How to assess preclinical dose formulation homogeneity. Pharm Technol. 2012;36(7):90–1.
4. Whitmire ML, Bryan P, Henry TR, Holbrook J, Lehmann P, Mollitor T, et al. Nonclinical dose formulation analysis method validation and sample analysis. AAPS J. 2010;12(4):628–34.
5. Barrett P, Glennon B. In-line FBRM monitoring of particle size in dilute agitated suspensions. Part Part Syst Charact. 1999;16(5):207–11.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献